Oncology Central

Immunotherapy for ovarian cancer: what are the targets of the future?


Ovarian Cancer

Epithelial ovarian cancer affects approximately one in 70 women and is characterized by presentation at late stages resulting in poor survival outcomes, with only 45% of women surviving 5 years after diagnosis [1]. Standard treatment of ovarian cancer includes surgery and cytotoxic chemotherapy. Unfortunately, although up to 80% of women achieve clinical remission with this regimen, the majority will experience relapsed disease, the development of chemotherapy resistance, and death due to cancer-associated morbidity [2].

To view restricted content, please:

Leave A Comment